PSC
GLUE icon

Piper Sandler & Co’s Monte Rosa Therapeutics GLUE Stock Holding History

Piper Sandler & Co’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,300
Closed -$51K – 23
2021
Q3 		$51K Buy
+2,300
New +$65.9K 0.07% 15

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Piper Sandler & Co's GLUE Position: Q4 2021 in Review

Piper Sandler & Co sold out of Monte Rosa Therapeutics (GLUE) in Q4 2021, closing a stake of 2,300 shares — an estimated $51K sold.

Piper Sandler & Co first reported a position in GLUE in Q3 2021 and held it in 1 quarter. The position peaked at $51K in Q3 2021. 53 funds tracked by Wall St. Rank hold GLUE as of Q4 2021.

  • Piper Sandler & Co reported no remaining Monte Rosa Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Piper Sandler & Co sold 2,300 Monte Rosa Therapeutics shares in Q4 2021, an estimated $51K.
  • Piper Sandler & Co first reported a position in Monte Rosa Therapeutics in Q3 2021 and held it in 1 quarter.
  • Piper Sandler & Co's Monte Rosa Therapeutics position peaked at $51K in Q3 2021.
  • 53 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2021.

Based on Piper Sandler & Co's 13F filing for Q4 2021, filed 14 Feb 2022.